Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients

Circulation: Heart Failure

Volumn 11, Issue 2, 2018, Pages

  Beverborg, Niels Grote ^a   Klip, IJsbrand T ^a   Meijers, Wouter C ^a   Voors, Adriaan A ^a   Vegter, Eline L ^a   Van Der Wal, Haye H ^a   Swinkels, Dorine W ^b   Van Pelt, Joost ^a   Mulder, Andre B ^a   Bulstra, Sjoerd K ^a   Vellenga, Edo ^a   Mariani, Massimo A ^a   De Boer, Rudolf A ^a   Van Veldhuisen, Dirk J ^a   Van Der Meer, Peter ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone marrow; Ferric carboxymaltose; Ferritin; Heart failure; Prognosis; Transferrin saturation

Indexed keywords

FERRITIN; HEPCIDIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; BIOLOGICAL MARKER; IRON DERIVATIVE;

AGED; ALL CAUSE MORTALITY; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ERYTHROBLAST; FEMALE; FERRITIN BLOOD LEVEL; GOLD STANDARD; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; MALE; PROGNOSIS; PRUSSIAN BLUE STAINING; SENSITIVITY AND SPECIFICITY; STERNOTOMY; VENOUS BLOOD; BLOOD; BONE MARROW; DEFICIENCY; HEART LEFT VENTRICLE FUNCTION; IRON DEFICIENCY ANEMIA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STAINING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; BONE MARROW; FEMALE; FERRITINS; HEART FAILURE; HUMANS; IRON; IRON COMPOUNDS; MALE; MIDDLE AGED; PROGNOSIS; STAINING AND LABELING; VENTRICULAR FUNCTION, LEFT;

EID: 85048508231     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.004519     Document Type: Article

References (32)

1. Klip IT, Comin-Colet J, Voors AA, Ponikowski P, Enjuanes C, Banasiak W, Lok DJ, Rosentryt P, Torrens A, Polonski L, van Veldhuisen DJ, van der Meer P, Jankowska EA. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165:575.e3–582.e3. doi: 10.1016/j. ahj.2013.01.017.
2. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Poni-kowska B, Borodulin-Nadzieja L, Banasiak W, Polonski L, Filippatos G, McMurray JJ, Anker SD, Ponikowski P. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872–1880. doi: 10.1093/eurheartj/ehq158.
3. Okonko DO, Mandal AK, Missouris CG, Poole-Wilson PA. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol. 2011;58:1241–1251. doi: 10.1016/j.jacc.2011.04.040.
4. van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol. 2011;8:485–493. doi: 10.1038/nrcardio.2011.77.
5. Harris S, Tepper D, Ip R. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency-ferric-HF: A randomized, controlled, observer-blinded trial. Congest Hear Fail. 2009;15:208.
6. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drex-ler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436–2448. doi: 10.1056/ NEJMoa0908355.
7. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36:657–668. doi: 10.1093/eurheartj/ehu385.
8. Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis [published online ahead of print April 24, 2017]. Eur J Heart Fail. doi: 10.1002/ejhf.823. http://onlinelibrary.wiley.com.proxy-ub.rug.nl/doi/10.1002/ejhf.823/epdf.
9. Weiss G, Goodnough LT. Anemia of chronic disease. Inflammation. 2012;352:1011–1023.
10. Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am J Cardiol. 2013;112:831–837. doi: 10.1016/j.amjcard.2013.05.013.
11. Garcia-Casal MN, Peña-Rosas JP, Pasricha SR. Rethinking ferritin cutoffs for iron deficiency and overload. Lancet Haematol. 2014;1:e92–e94. doi: 10.1016/S2352-3026(14)00025-8.
12. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Do-letsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A; EFFECT-HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation. 2017;136:1374–1383. doi: 10.1161/CIRCULATIONAHA.117.027497.
13. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoy-annopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/eurheartj/ehw128.
14. Baumgartner-Stäubli R, Beck EA. Sideroblast score: a sensitive indicator of iron deficiency and hypoproliferative anemia. Acta Haematol. 1977;57:24–31.
15. Hansen HA, Weinfeld A. Hemosiderin estimations and sideroblast counts in the differential diagnosis of iron deficiency and other anemias. Acta Med Scand. 1959;165:333–356.
16. Gale E, Torrance J, Bothwell T. The quantitative estimation of total iron stores in human bone marrow. J Clin Invest. 1963;42:1076–1082. doi: 10.1172/JCI104793.
17. Phiri KS, Calis JC, Kachala D, Borgstein E, Waluza J, Bates I, Brabin B, van Hensbroek MB. Improved method for assessing iron stores in the bone marrow. J Clin Pathol. 2009;62:685–689. doi: 10.1136/jcp.2009.064451.
18. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pick-kers P, van Ede AE, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56:1570–1579. doi: 10.1373/clinchem.2010.149187.
19. Beilby J, Olynyk J, Ching S, Prins A, Swanson N, Reed W, Harley H, Garcia-Webb P. Transferrin index: an alternative method for calculating the iron saturation of transferrin. Clin Chem. 1992;38:2078–2081.
20. WHO Scientific Group. Nutritional anaemias. Report of a WHO group of experts. World Health Organ Tech Rep Ser. 1972;503:1–29. http://apps.who.int/iris/bitstream/10665/40977/1/WHO_TRS_503.pdf.
21. Punnonen K, Irjala K, Rajamäki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89:1052–1057.
22. Matsushita K, Mahmoodi BK, Woodward M, Emberson JR, Jafar TH, Jee SH, Polkinghorne KR, Shankar A, Smith DH, Tonelli M, Warnock DG, Wen CP, Coresh J, Gansevoort RT, Hemmelgarn BR, Levey AS; Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941–1951. doi: 10.1001/ jama.2012.3954.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–845.
24. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, Swed-berg K, Dobson J, Poppe KK, Whalley GA, Doughty RN; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34:1404–1413. doi: 10.1093/eurheartj/ehs337.
25. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anasta-siou-Nana MI. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48:2485–2489. doi: 10.1016/j.jacc.2006.08.034.
26. Jankowska EA, Wojtas K, Kasztura M, Mazur G, Butrym A, Kalicinska E, Rybinska I, Skiba J, von Haehling S, Doehner W, Anker SD, Banasiak W, Cleland JG, Ponikowski P. Bone marrow iron depletion is common in patients with coronary artery disease. Int J Cardiol. 2015;182:517–522. doi: 10.1016/j.ijcard.2014.10.006.
27. Moliner P, Jankowska EA, van Veldhuisen DJ, Farre N, Rozentryt P, Enjuanes C, Polonski L, Meroño O, Voors AA, Ponikowski P, Van der Meer P, Comin-Colet J. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. Int J Cardiol. 2017;243:360–366. doi: 10.1016/j.ijcard.2017.04.110.
28. Beck-Da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, De Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168:3439–3442.
29. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657–1665. doi: 10.1016/j.jacc.2007.07.029.
30. Wood JC. Guidelines for quantifying iron overload. Hematology Am Soc Hematol Educ Program. 2014;2014:210–215. doi: 10.1182/asheducation-2014.1.210.
31. Dale JC, Burritt MF, Zinsmeister AR. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol. 2002;117:802–808. doi: 10.1309/2YT4-CMP3-KYW7-9RK1.
32. Ridefelt P, Larsson A, Rehman JU, Axelsson J. Influences of sleep and the circadian rhythm on iron-status indices. Clin Biochem. 2010;43:1323–1328. doi: 10.1016/j.clinbiochem.2010.08.023.